Data for patients (n = 157) treated in Edinburgh with malignant glioma (1989-1995) who would have been eligible for the MRC brain tumour trial protocols are included in this table (patients > 70 years and not receiving radiotherapy have been excluded)
| MRC score | n | Survival time (weeks) median | (95% Cl) | Survival for 2 y | (95% Cl) |
|---|---|---|---|---|---|
| 1–10 | 19 | Not reached | — | 77.0 | (60–100) |
| 11–15 | 25 | 85 | (55–128) | 37.0 | (21–65) |
| 16–20 | 28 | 67 | (40–—) | 36.0 | (21–60) |
| 21–25 | 33 | 41 | (30–91) | 24.0 | (13–45) |
| 26–33 | 43 | 44 | (40–54) | 3.9 | (1–23) |
| 34–38 | 9 | 28 | (19–—) | 0.0 | — |
The comparative outcomes from the BR-2 study are; MRC score 1-10, median survival time 80 weeks, 2 year survival 39%; score 11-15, 76 weeks, 33%; score 16-20, 46 weeks, 16%; score 21-25, 33 weeks, 7%; score 28 weeks, 0%; and score 34-38, 19 weeks, 0%.